BR0207819A - Proteìna, citocina, il-13 humano mutado, polinucleotìdeo, vetor, hospedeiro, composição farmacêutica, uso de uma proteìna, métodos para o tratamento de profilaxia de doença mediada por il-13, e para a preparação de uma proteìna - Google Patents

Proteìna, citocina, il-13 humano mutado, polinucleotìdeo, vetor, hospedeiro, composição farmacêutica, uso de uma proteìna, métodos para o tratamento de profilaxia de doença mediada por il-13, e para a preparação de uma proteìna

Info

Publication number
BR0207819A
BR0207819A BR0207819-8A BR0207819A BR0207819A BR 0207819 A BR0207819 A BR 0207819A BR 0207819 A BR0207819 A BR 0207819A BR 0207819 A BR0207819 A BR 0207819A
Authority
BR
Brazil
Prior art keywords
protein
preparation
methods
cytokine
vector
Prior art date
Application number
BR0207819-8A
Other languages
English (en)
Inventor
Claire Asham
James Scott Crowe
Jonathan Henry Ellis
Alan Peter Lewis
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR0207819A publication Critical patent/BR0207819A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"PROTEìNA, CITOCINA, IL-13 HUMANO MUTADO, POLINUCLEOTìDEO, VETOR, HOSPEDEIRO, COMPOSIçãO FARMACêUTICA, USO DE UMA PROTEìNA, MéTODOS PARA O TRATAMENTO DE PROFILAXIA DE DOENçA MEDIADA POR IL-13, E PARA A PREPARAçãO DE UMA PROTEìNA". A presente invenção refere-se a um polipeptídeo isolado utilizável para imunização contra auto-antígenos. Particularmente, a invenção refere-se a uma auto-proteína que é capaz de criar auto-anticorpos quando administrada in vivo. A invenção particularmente refere-se a tornar citocinas humanas imunogênicas em humanos. A invenção ainda refere-se a composições farmacêuticas compreendendo estes compostos e seu uso em medicina e a métodos para sua produção.
BR0207819-8A 2001-03-03 2002-03-01 Proteìna, citocina, il-13 humano mutado, polinucleotìdeo, vetor, hospedeiro, composição farmacêutica, uso de uma proteìna, métodos para o tratamento de profilaxia de doença mediada por il-13, e para a preparação de uma proteìna BR0207819A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0105360.2A GB0105360D0 (en) 2001-03-03 2001-03-03 Chimaeric immunogens
PCT/GB2002/000900 WO2002070711A1 (en) 2001-03-03 2002-03-01 Vaccine

Publications (1)

Publication Number Publication Date
BR0207819A true BR0207819A (pt) 2004-03-02

Family

ID=9909970

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207819-8A BR0207819A (pt) 2001-03-03 2002-03-01 Proteìna, citocina, il-13 humano mutado, polinucleotìdeo, vetor, hospedeiro, composição farmacêutica, uso de uma proteìna, métodos para o tratamento de profilaxia de doença mediada por il-13, e para a preparação de uma proteìna

Country Status (18)

Country Link
US (3) US20050260216A1 (pt)
EP (1) EP1368477A1 (pt)
JP (1) JP4238031B2 (pt)
KR (1) KR20030081490A (pt)
CN (1) CN1543504A (pt)
AU (1) AU2002233560B2 (pt)
BR (1) BR0207819A (pt)
CA (1) CA2439628A1 (pt)
CZ (1) CZ20032373A3 (pt)
GB (1) GB0105360D0 (pt)
HU (1) HUP0303372A3 (pt)
IL (1) IL157498A0 (pt)
MX (1) MXPA03007915A (pt)
NO (1) NO20033882L (pt)
NZ (1) NZ527873A (pt)
PL (1) PL365066A1 (pt)
WO (1) WO2002070711A1 (pt)
ZA (1) ZA200306647B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02003108A (es) * 1999-09-25 2003-10-14 Univ Iowa Res Found Acidos nucleicos inmunoestimuladores.
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
WO2004019974A2 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
WO2004019975A2 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
CA2498739A1 (en) * 2002-09-12 2004-03-25 Pharmexa A/S Immunization against autologous ghrelin
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
ZA200506202B (en) * 2003-01-31 2006-10-25 Celldex Therapeutics Inc Antibody vaccine conjugates and uses therefor
CA2519114A1 (en) * 2003-03-24 2004-10-07 Mercia Pharma, Inc. Methods and compositions for treating and preventing inflammatory conditions
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
PT1767216E (pt) * 2004-06-11 2012-08-27 Riken Fármaco tendo um ligando de células reguladoras contido num lipossoma
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2486938T (pt) 2006-09-26 2018-06-12 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
EP2137215A2 (en) * 2007-04-23 2009-12-30 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
JP2010527633A (ja) * 2007-05-25 2010-08-19 セントコア・オーソ・バイオテツク・インコーポレーテツド Ｔｏｌｌ様受容体３モジュレーター及びその使用
EP2570137A3 (en) * 2007-11-07 2013-08-21 Celldex Therapeutics, Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EA034351B1 (ru) 2012-05-16 2020-01-30 Иммьюн Дизайн Корп. Трехкомпонентная вакцина против впг-2 и способы ее применения
BR112015025709A2 (pt) 2013-04-18 2017-07-18 Immune Design Corp monoterapia com gla para uso em tratamento de câncer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
JP2024505525A (ja) * 2021-01-29 2024-02-06 エランコ アニマル ヘルス ゲー・エム・ベー・ハー 自己寛容を破壊するためのワクチン組成物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
AU661684B2 (en) * 1991-06-18 1995-08-03 Regents Of The University Of California, The Cloned glutamic acid decarboxylase
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
WO1996002555A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
CN1117155C (zh) * 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
EP0815136B1 (en) * 1995-02-20 2007-06-13 The Walter And Eliza Hall Institute Of Medical Research Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)
US6518061B1 (en) * 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
EP0759468A1 (en) * 1995-08-10 1997-02-26 Laboratoires Virbac Feline interleukin-4
US5666153A (en) * 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
EP0911401A1 (en) * 1997-10-21 1999-04-28 Bayer Ag Muteins of interleukin 4 showing low-affinity and short-term interaction with the common gamma chain
JP2002506618A (ja) * 1998-03-20 2002-03-05 ジェンザイム・コーポレーション 腫瘍自己抗原に対する免疫誘導
US6576232B1 (en) * 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
AU5617900A (en) * 1999-06-17 2001-01-09 Robert C. Gallo Chimeric chemokine-antigen polypeptides and uses therefor
CA2404763A1 (en) * 1999-11-11 2001-05-17 Raj K. Puri Mutated il-13 molecules and their uses

Also Published As

Publication number Publication date
KR20030081490A (ko) 2003-10-17
PL365066A1 (en) 2004-12-27
CZ20032373A3 (cs) 2004-01-14
US20050186209A1 (en) 2005-08-25
WO2002070711A1 (en) 2002-09-12
HUP0303372A2 (hu) 2004-01-28
NZ527873A (en) 2005-12-23
NO20033882D0 (no) 2003-09-02
HUP0303372A3 (en) 2008-06-30
IL157498A0 (en) 2004-03-28
NO20033882L (no) 2003-10-31
MXPA03007915A (es) 2003-12-04
ZA200306647B (en) 2004-11-26
EP1368477A1 (en) 2003-12-10
JP4238031B2 (ja) 2009-03-11
CN1543504A (zh) 2004-11-03
CA2439628A1 (en) 2002-09-12
AU2002233560B2 (en) 2006-09-07
GB0105360D0 (en) 2001-04-18
JP2005502314A (ja) 2005-01-27
US20030194391A1 (en) 2003-10-16
US20050260216A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
BR0207819A (pt) Proteìna, citocina, il-13 humano mutado, polinucleotìdeo, vetor, hospedeiro, composição farmacêutica, uso de uma proteìna, métodos para o tratamento de profilaxia de doença mediada por il-13, e para a preparação de uma proteìna
BR0207283A (pt) Anticorpos anti-egfr modificados com imunogenicidade reduzida
ES2676824T3 (es) Proteínas GST de 28 KDa que provienen de esquistosomas para su utilización en el tratamiento de enfermedades inflamatorias autoinmunes que generan una respuesta de tipo Th1 y/o Th17
JP2004501101A5 (pt)
BR0206289A (pt) Processos de administração de anticorpos anti-tnf(alfa)
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
BRPI0415304A (pt) métodos de aumentar uma resposta imune a um antìgeno em um mamìfero, e de reduzir a severidade de um cáncer em um paciente, preparação combinada, kit farmacêutico, e, usos de um polipeptìdeo de il-18 ou seu fragmento ou variante bioativos, e de uma composição imunogênica
HUP0000299A1 (hu) Késleltetett hatóanyag-leadású gyógyszerkészítmények
BR0114786A (pt) Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
BRPI0415315A (pt) métodos de aumentar uma resposta imune a um antìgeno em um mamìfero, e de reduzir a severidade de um cáncer em um paciente, preparação combinada, kit farmacêutico, e, usos de um polipeptìdeo de il-18 ou seu fragmento ou derivado bioativos, e de uma composição imunogênica
CA2688766C (en) Compositions and methods for treatment of multiple sclerosis
AU1813701A (en) Interleukin-1 muteins useful as vaccine adjuvants
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
Zhang et al. Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum)
WO2002074783A3 (en) Modified interferon beta with reduced immunogenicity
EP1556513A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS
BR0207018A (pt) Leptina modificada com imunogenicidade reduzida
KR20070012801A (ko) 인터페론-타우에 의한 치료를 최적화하는 방법
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
WO2002081507A3 (en) Interferon gamma polypeptide variants
JP2005530723A (ja) 新規ペプチド及び治療を目的とするその利用
BR0207014A (pt) Antagonista de receptor de interleucina-1 modificada (il-1ra) com imunogenicidade reduzida.
BR0207705A (pt) Fator neurotrófico ciliar modificado (cntf) com imonogenicidade reduzida
AU2016319292A1 (en) Use of interleukin 2 for treating spondyloarthritis
BR0207905A (pt) Protamina modificada com imunogenicidade reduzida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2055 DE 25/05/2010.